EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

A Phase IIb , single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments

Binghe Xu iD, Fei Ma, Tao Wang, Shusen Wang iD, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang und 6 weitere

International Journal of Cancer · 2023

DOI: 10.1002/ijc.34424 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Binghe Xu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Immunoconjugates. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Refractory or relapsing metastatic triple‐negative breast cancer (mTNBC) has a poor prognosis. Sacituzumab govitecan (SG) is a novel antibody‐drug conjugate, targeting human trophoblast cell‐surface antigen 2 (Trop‐2). This is the first report of SG's efficacy and safety in Chinese patients with mTNBC. EVER‐132‐001 (NCT04454437) was a multicenter, single‐arm, Phase IIb study in Chinese patients with mTNBC who failed ≥2 prior chemotherapy regimens. Eligible patients received 10 mg/kg SG on Days 1 and 8 of each 21‐day treatment cycle, until disease progression/unacceptable toxicity. The primary endpoint was objective response rate (ORR) assessed by the Independent Review Committee. Secondary endpoints included: duration of response (DOR), clinical benefit rate (CBR), progression‐free survival (PFS), overall survival (OS) and safety. Eighty female Chinese patients (median age 47.6 years; range 24‐69.9 years) received ≥1 SG dose with a median of 8 treatment cycles by the cutoff date (August 6, 2021). Median number of prior systemic cancer treatments was 4.0 (range 2.0‐8.0). ORR and CBR were reported 38.8% (95% confidence interval [CI]: 28.06‐50.30) and 43.8% (95% CI, 32.68‐55.30) of patients, respectively. The median PFS was 5.55 months (95% CI, 4.14‐N/A). SG‐related Grade ≥3 treatment‐emergent adverse events (TEAEs) were reported in 71.3%, the most common were neutrophil count decreased (62.5%), white blood cell count decreased (48.8%) and anemia (21.3%); 6.3% discontinued SG because of TEAEs. SG demonstrated substantial clinical activity in heavily pretreated Chinese patients with mTNBC. The observed safety profile was generally manageable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsImmunoconjugatesHumansFemaleMiddle AgedEast Asian PeopleNeoplasm Recurrence, LocalCamptothecinAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

ChinaTrop-2antibody drug conjugatesacituzumab govitecantriple-negative breast cancer

Substanzen

CamptothecinImmunoconjugatessacituzumab govitecanAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Breast Cancer, The Fifth Medical Center of PLA General Hospital, Beijing, China.
  • Department of Medical Oncology, Sun Yet-Sen University Cancer Center, Guangzhou, China.
  • Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Department of Medical Oncology, The First Hospital of Jilin University, Changchun, China.
  • Department of Breast Oncology, Hubei Cancer Hospital, Wuhan, China.

ORCID-Profile: Binghe Xu, Shusen Wang

Zitieren

APA

Xu, B., Ma, F., Wang, T., Wang, S., Tong, Z., Li, W., Wu, X., Wang, X., Sun, T., Pan, Y., Yao, H., Wang, X., Luo, T., Yang, J., Zeng, X., Zhao, W., Cong, X. J., & Chen, J. (2023). A Phase IIb , single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments. International Journal of Cancer. https://doi.org/10.1002/ijc.34424

Vancouver

Xu B, Ma F, Wang T, Wang S, Tong Z, Li W, et al. A Phase IIb , single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments. International Journal of Cancer. 2023. doi:10.1002/ijc.34424

BibTeX
@article{Xu2023,
  author = {Xu, Binghe and Ma, Fei and Wang, Tao and Wang, Shusen and Tong, Zhongsheng and Li, Wei and Wu, Xinhong and Wang, Xiaojia and Sun, Tao and Pan, Yueyin and Yao, Herui and Wang, Xian and Luo, Ting and Yang, Jin and Zeng, Xiaohua and Zhao, Weihong and Cong, Xiuyu Julie and Chen, Jiongjie},
  title = {A Phase IIb , single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments},
  journal = {International Journal of Cancer},
  year = {2023},
  doi = {10.1002/ijc.34424}
}
Kostenlos starten →